Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome

Geoffrey Chan, Gina DiVenuti, Kenneth B. Miller, Kenneth Miller
American journal of hematology · 2002 · vol. 71(3) , pp. 166–171 · doi:10.1002/ajh.10209 · PMID:12410570 · W1979934252
Observational OA: closed CC0 ⤵ 12 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

Danazol treatment for 6 or 12 weeks increased platelet counts in myelodysplastic syndrome patients, reduced transfusion needs, and was well tolerated.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Thrombocytopenia is a poor prognostic indicator in the myelodysplastic syndromes (MDS). Treatment options for patients with symptomatic thrombocytopenia are limited. Danazol, an attenuated androgen, may have some efficacy in increasing the platelet count of patients with MDS. We retrospectively reviewed 33 patients with primary MDS who were treated with danazol for 6 or more weeks. After 6 weeks on danazol, the mean platelet count increased from 42 x 10(9)/L to 60 x 10(9)/L (P < 0.015), and 25 out of 33 patients (76%) had an increase in their platelet counts. Following 12 weeks of treatment, the mean platelet count increased to 67 x 10(9)/L (P < 0.005), and 21 out of 29 patients (72%) had an increase in their platelet counts. Seven out of nine patients no longer required platelet transfusions because bleeding stopped after 6 weeks on danazol. Mean duration of response was 10 months (range 2-68 months). Responses were seen in all French-American-British (FAB) subtypes and in all International Prognostic Scoring System (IPSS) scores. Therapy was well tolerated. Danazol may be effective in MDS patients who are thrombocytopenic.

My notes (saved in your browser only)

MeSH descriptors

Danazol Myelodysplastic Syndromes Thrombocytopenia Thrombocytopenia Adult Aged Aged, 80 and over Androgens Androgens Danazol Danazol Female Humans Male Middle Aged Myelodysplastic Syndromes Platelet Count Retrospective Studies Thrombocytopenia Thrombocytopenia

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (23)

Cited by (7)

Source provenance

openalex
last seen: 2026-05-11T06:08:11.709964+00:00
pubmed
last seen: 2026-10-08T21:00:45.472718+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK